Met-CCL5 is a CCL5 receptor antagonist, which is used extensively to block the pathogenic effects of CCL5 and attenuate CCR5-mediated inflammatory processes during the development of arthritis, colitis, airway inflammation, allograft rejection and chronic liver diseases [46-50]. This evidence concerns the gene CCL5 and arthritic joint disease.